Abstract | OBJECTIVE: METHODS: By retrospective analysis of the patients' files in the hospitals of Paris-Salpêtrière (n=91), Montpellier (n=40) and Lyon (n=8), the benefit (Epworth Sleepiness Score (ESS), cataplexy frequency, authorization renewal) and tolerance (side-effects, vital signs, electrocardiogram and cardiac echography) of mazindol were assessed. RESULTS: The 139 patients (45% men) aged 36±15years (range: 9-74) suffered narcolepsy (n=94, 66% with cataplexy), idiopathic (n=37) and symptomatic hypersomnia (n=8) refractory to modafinil, methylphenidate and sodium oxybate. Under mazindol (3.4±1.3mg/day, 1-6mg) for an average of 30months, the ESS decreased from 17.7±3.5 to 12.8±5.1, with an average fall of -4.6±4.7 (p<0.0001) and the frequency of cataplexy fell from 4.6±3.1 to 2±2.8 episodes per week. The cataplexy was eliminated in 14.5% of patients, improved in 27.5%, and unchanged in 29% (missing data in 29%). The treatment was maintained long term in 83 (60%) patients, and stopped because of a lack of efficacy (22%) and/or secondary effects (9%). There was no pulmonary hypertension in the 45 patients who underwent a cardiac echography. The most common adverse effects were dry mouth (13%), palpitations (10%, including one with ventricular hyperexcitability), anorexia (6%), nervousness (6%) and headaches (6%). CONCLUSION:
Mazindol has a long-term, favorable benefit/risk ratio in 60% of drug-resistant hypersomniacs, including a clear benefit on cataplexy.
|
Authors | Nandini Nittur, Eric Konofal, Yves Dauvilliers, Patricia Franco, Smaranda Leu-Semenescu, Valérie Cochen De Cock, Clara O Inocente, Sophie Bayard, Sabine Scholtz, Michel Lecendreux, Isabelle Arnulf |
Journal | Sleep medicine
(Sleep Med)
Vol. 14
Issue 1
Pg. 30-6
(Jan 2013)
ISSN: 1878-5506 [Electronic] Netherlands |
PMID | 23036267
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 Elsevier B.V. All rights reserved. |
Chemical References |
- Central Nervous System Stimulants
- Mazindol
|
Topics |
- Adolescent
- Adult
- Aged
- Blood Pressure
(drug effects)
- Cataplexy
(drug therapy)
- Central Nervous System Stimulants
(adverse effects, therapeutic use)
- Child
- Female
- Heart Rate
(drug effects)
- Humans
- Idiopathic Hypersomnia
(drug therapy)
- Male
- Mazindol
(adverse effects, therapeutic use)
- Middle Aged
- Narcolepsy
(drug therapy)
- Retrospective Studies
- Wakefulness
(drug effects)
- Young Adult
|